Literature DB >> 17053039

Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers.

Sungtae Kim1, Miwa Yamazaki, Nirupama K Shevde, J Wesley Pike.   

Abstract

Receptor activator of nuclear factor-kappaB ligand (RankL) is a potent osteoclastogenic cytokine the expression of which is regulated at the transcriptional level by 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], protein kinase A (PKA) activators such as PTH and transmembrane glycoprotein 130 (gp130)-activating cytokines such as oncostatin M. We recently identified five highly conserved chromatin domains located significant distances upstream of the RankL transcriptional start site that contribute to the ability of 1,25-(OH)2D3 and its receptor to enhance RankL gene output. We therefore screened these five common regulatory regions for their potential ability to mediate the actions of PKA- and gp130-activators using a directed chromatin immunoprecipitation approach employing antibodies to the PKA target cAMP response element-binding protein (CREB) and the gp130 target signal transducer and activator of transcription 3. CREB was identified at each of the upstream regulatory regions; signal transducer and activator of transcription 3, in contrast, was associated with only a subset. Interestingly, only the most distal of these regions demonstrated CREB- and oncostatin M-regulated transcriptional activity in a heterologous transfection system. Mapping studies pointed to two highly conserved cAMP response elements as well as an adjacent regulatory site that bound Runt transcription factor 2 and was able to influence both basal as well as hormone-inducible RankL activity. Surprisingly, PKA and gp130 activation prompted recruitment of RNA polymerase II to the five distal enhancers as well as to the RankL transcriptional start site. Activation was also accompanied by a significant and location-selective rise in histone 4 acetylation. This study demonstrates that the activation of RankL gene expression by PKA- and gp130-inducers is mediated via common regulatory domains that also served to facilitate the activity of 1,25-(OH)2D3.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053039     DOI: 10.1210/me.2006-0315

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  32 in total

Review 1.  Genome-scale techniques highlight the epigenome and redefine fundamental principles of gene regulation.

Authors:  J Wesley Pike
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

2.  The osteoblast to osteocyte transition: epigenetic changes and response to the vitamin D3 hormone.

Authors:  Hillary C St John; Kathleen A Bishop; Mark B Meyer; Nancy A Benkusky; Ning Leng; Christina Kendziorski; Lynda F Bonewald; J Wesley Pike
Journal:  Mol Endocrinol       Date:  2014-05-30

3.  Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region.

Authors:  Kathleen A Bishop; Heidi M Coy; Robert D Nerenz; Mark B Meyer; J Wesley Pike
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

Review 4.  Genome-wide principles of gene regulation by the vitamin D receptor and its activating ligand.

Authors:  J Wesley Pike
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

5.  A DNA segment spanning the mouse Tnfsf11 transcription unit and its upstream regulatory domain rescues the pleiotropic biologic phenotype of the RANKL null mouse.

Authors:  Melda Onal; Kathleen A Bishop; Hillary C St John; Allison L Danielson; Erin M Riley; Marilina Piemontese; Jinhu Xiong; Joseph J Goellner; Charles A O'Brien; J Wesley Pike
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

6.  An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3.

Authors:  Robert D Nerenz; Melissa L Martowicz; J Wesley Pike
Journal:  Mol Endocrinol       Date:  2008-01-17

Review 7.  Regulation of gene expression by 1,25-dihydroxyvitamin D3 in bone cells: exploiting new approaches and defining new mechanisms.

Authors:  J Wesley Pike; Seong Min Lee; Mark B Meyer
Journal:  Bonekey Rep       Date:  2014-01-08

8.  A novel distal enhancer mediates cytokine induction of mouse RANKl gene expression.

Authors:  Kathleen A Bishop; Mark B Meyer; J Wesley Pike
Journal:  Mol Endocrinol       Date:  2009-10-30

9.  Deletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice.

Authors:  Melda Onal; Hillary C St John; Allison L Danielson; J Wesley Pike
Journal:  J Bone Miner Res       Date:  2016-02       Impact factor: 6.741

10.  Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH.

Authors:  Changjun Li; Qiujuan Xing; Bing Yu; Hui Xie; Weishan Wang; Chenhui Shi; Janet L Crane; Xu Cao; Mei Wan
Journal:  J Bone Miner Res       Date:  2013-10       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.